Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.
Price
Target price
€144.92

€144.92

-1.530%
-2.24
-1.530%
€192.16
 
22:26 / Tradegate WKN: A1KBYX / Symbol: ZTS / Name: Zoetis / Stock / Pharmaceuticals / Large Cap /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
JavaScript chart by amCharts 3.21.15
JavaScript chart by amCharts 3.21.15
JavaScript chart by amCharts 3.21.15JS chart by amCharts
Select a timeframe to show chart data
From: to:
Zoom:
Your prediction

Zoetis Inc. A Stock

A loss of -1.530% shows a downward development for Zoetis Inc. A.
Zoetis Inc. A is currently one of the favorites of our community with 19 Buy predictions and no Sell predictions.
With a target price of 192 € there is a positive potential of 32.49% for Zoetis Inc. A compared to the current price of 144.92 €.
So far the community has only identified positive things for Zoetis Inc. A stock. The most positive votes were given for criterium "Business model".

Pros and Cons of Zoetis Inc. A in the next few years

Pros
?
W********* I********* f** t** n*** y****
?
G***** c******* t* c**********
?
M***** P*******
Cons
?
B****
?
C******** o* t** e**********
?
S********** s********
Tell us your opinion to access the 'Wisdom of the Crowds'

Performance of Zoetis Inc. A vs. its peers

Security Change(%) 1w 1m 1y YTD 3y 5y
Zoetis Inc. A -1.530% -2.376% 3.364% -12.029% -6.698% -4.741% 19.027%
Elanco Animal Health Inc. -0.910% 4.931% 16.936% -26.687% 7.620% -41.322% -38.475%
Johnson & Johnson -1.450% 0.854% 0.000% 0.161% -1.510% -16.486% 5.597%
Biogen Inc. -2.020% 2.241% 13.006% -43.551% -17.667% -36.834% -54.244%

sharewise BeanCounterBot

The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.
Last updated at 2023-12-04

When examining the financials of Zoetis (NYSE: ZTS), a leading company in the pharmaceutical industry, a preliminary review reveals a robust picture with consistent growth in total assets over the last three years. This growth is coupled with a stable increase in shareholder equity, indicating prudent financial management and a strong balance sheet foundation. A deeper dive into the detailed numbers should provide further insights into the organization's financial health, as well as potential areas of caution.

Growing Top Line: Zoetis has demonstrated a steady increase in total revenues, with the trailing twelve-month (TTM) revenue at approximately $8.37 billion. The year-over-year quarterly revenue growth of 7.4% signals a solid capacity for expanding their market presence and sales effectiveness.

EBITDA and Operating Margins: The EBITDA and operating margins are notable strengths, with a TTM EBITDA of around $3.47 billion and an operating margin of 37.1%. These numbers suggest efficient operational management and profitability.

Comments

Prediction Buy
Perf. (%) -1.58%
Target price 187.068
Change
Ends at 12.05.26

Zoetis Inc. (NYSE: ZTS) had its price target raised by analysts at Piper Sandler from $205.00 to $210.00. They now have an "overweight" rating on the stock.
Ratings data for ZTS provided by MarketBeat
Show more

Prediction Buy
Perf. (%) 9.19%
Target price 144.903
Change
Ends at 14.04.26

Zoetis Inc. (NYSE: ZTS) had its price target lowered by analysts at Stifel Nicolaus from $180.00 to $165.00. They now have a "buy" rating on the stock.
Ratings data for ZTS provided by MarketBeat
Show more

Prediction Buy
Perf. (%) -8.10%
Target price 196.616
Change
Ends at 27.02.26

Zoetis Inc. (NYSE: ZTS) had its price target raised by analysts at Piper Sandler from $200.00 to $205.00. They now have an "overweight" rating on the stock.
Ratings data for ZTS provided by MarketBeat
Show more

News

2 Recession-Proof Stocks to Buy and Hold: https://g.foolcdn.com/editorial/images/820106/pet-owners-walking-their-dog.jpg
2 Recession-Proof Stocks to Buy and Hold

President Trump's trade policies are sparking concerns about a potential recession. Though it's hard to predict an upcoming economic downturn, it's never a bad idea for investors to buy shares of

Beat the S&P 500 With This Cash-Gushing Dividend Stock: https://g.foolcdn.com/editorial/images/819685/veterinarian-cat-sick-pet-health.jpg
Beat the S&P 500 With This Cash-Gushing Dividend Stock

You don't need to uncover the next big artificial intelligence stock to outperform the broader stock market. Sometimes, consistent and profitable growth is all you need to achieve outsize investment

1 Superstar Dividend Growth Stock to Buy if the Market Crashes: https://g.foolcdn.com/editorial/images/815480/happy-pet-owner.jpg
1 Superstar Dividend Growth Stock to Buy if the Market Crashes

The stock market has entered a new period of increased uncertainty and volatility following the Trump Administration's desire to reshape America's trade policies. While the market hasn't crashed